Related Experiment Videos
[Proceedings: Erythrocyte 2,3-diphosphoglycerate during the development of myocardial infarct. Concerning 118 cases]
Schweizerische Medizinische Wochenschrift
|November 1, 1975
Insights
Elevated 2,3-diphosphoglycerate (2,3-DPG) levels in red blood cells indicate complications in myocardial infarction patients. This biomarker increase is associated with adverse outcomes, including patient mortality.
Area of Science:
- Biochemistry
- Cardiology
- Hematology
Context:
- Myocardial infarction (MI) is a leading cause of death globally.
- Understanding biomarkers associated with MI complications is crucial for patient management.
- Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) plays a role in oxygen transport.
Purpose:
- To investigate the association between erythrocyte 2,3-DPG concentration and complications in myocardial infarction patients.
- To determine if 2,3-DPG levels can serve as a predictive marker for adverse outcomes in MI.
Summary:
- A study involving four groups of myocardial infarction patients observed a significant increase in erythrocyte 2,3-DPG concentration.
- This elevation was notably correlated with the appearance of complications during the course of the disease or with patient mortality.
Impact:
- The findings suggest that erythrocyte 2,3-DPG may serve as a valuable biomarker for predicting complications and mortality in myocardial infarction.
- This could lead to improved patient monitoring and timely intervention strategies in cardiovascular care.
Abstract:
In four groups of patients with myocardial infarction the increase of 2.3-DPG concentration in erythrocyte was important when complications appeared during the evolution or when the patients died.